A detailed history of Barclays PLC transactions in Medicinova Inc stock. As of the latest transaction made, Barclays PLC holds 82,800 shares of MNOV stock, worth $171,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,800
Previous 82,800 -0.0%
Holding current value
$171,396
Previous $174,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$1.13 - $2.1 $451 - $840
-400 Reduced 0.48%
82,800 $174,000
Q1 2024

May 15, 2024

SELL
$1.28 - $1.65 $10,368 - $13,365
-8,100 Reduced 8.87%
83,200 $121,000
Q4 2023

Feb 15, 2024

SELL
$1.38 - $2.06 $17,250 - $25,750
-12,500 Reduced 12.04%
91,300 $137,000
Q3 2023

Nov 07, 2023

SELL
$2.01 - $2.6 $17,285 - $22,360
-8,600 Reduced 7.65%
103,800 $217,000
Q2 2023

Aug 03, 2023

SELL
$2.09 - $2.43 $55,802 - $64,881
-26,700 Reduced 19.19%
112,400 $259,000
Q1 2023

May 04, 2023

SELL
$1.95 - $2.54 $18,135 - $23,622
-9,300 Reduced 6.27%
139,100 $300,000
Q4 2022

Feb 13, 2023

SELL
$1.97 - $2.66 $19,503 - $26,334
-9,900 Reduced 6.25%
148,400 $304,000
Q3 2022

Nov 03, 2022

SELL
$2.1 - $2.6 $48,090 - $59,540
-22,900 Reduced 12.64%
158,300 $343,000
Q2 2022

Aug 12, 2022

SELL
$2.31 - $3.14 $7,854 - $10,676
-3,400 Reduced 1.84%
181,200 $458,000
Q1 2022

May 16, 2022

BUY
$2.19 - $2.81 $25,842 - $33,158
11,800 Added 6.83%
184,600 $493,000
Q4 2021

Feb 14, 2022

BUY
$2.61 - $4.42 $49,026 - $83,025
18,784 Added 12.2%
172,800 $463,000
Q3 2021

Nov 09, 2021

BUY
$3.4 - $4.24 $179,710 - $224,109
52,856 Added 52.25%
154,016 $584,000
Q2 2021

Aug 13, 2021

BUY
$3.76 - $5.14 $82,077 - $112,201
21,829 Added 27.52%
101,160 $430,000
Q1 2021

May 13, 2021

BUY
$4.81 - $8.74 $213,895 - $388,659
44,469 Added 127.56%
79,331 $401,000
Q4 2020

Feb 11, 2021

BUY
$5.03 - $6.31 $72,356 - $90,769
14,385 Added 70.25%
34,862 $184,000
Q3 2020

Nov 12, 2020

SELL
$4.67 - $11.0 $12,800 - $30,151
-2,741 Reduced 11.81%
20,477 $108,000
Q2 2020

Aug 12, 2020

BUY
$3.06 - $7.06 $28,604 - $65,996
9,348 Added 67.4%
23,218 $126,000
Q1 2020

May 13, 2020

SELL
$2.9 - $6.97 $81,954 - $196,972
-28,260 Reduced 67.08%
13,870 $52,000
Q4 2019

Feb 10, 2020

BUY
$6.48 - $8.76 $136,935 - $185,116
21,132 Added 100.64%
42,130 $284,000
Q3 2019

Nov 14, 2019

SELL
$7.7 - $10.42 $42,704 - $57,789
-5,546 Reduced 20.89%
20,998 $167,000
Q2 2019

Aug 14, 2019

BUY
$8.29 - $13.22 $119,798 - $191,042
14,451 Added 119.5%
26,544 $256,000
Q1 2019

May 15, 2019

BUY
$6.82 - $10.27 $50,283 - $75,720
7,373 Added 156.21%
12,093 $100,000
Q4 2018

Feb 14, 2019

SELL
$7.65 - $12.83 $78,190 - $131,135
-10,221 Reduced 68.41%
4,720 $39,000
Q3 2018

Nov 14, 2018

BUY
$7.06 - $12.49 $85,249 - $150,816
12,075 Added 421.32%
14,941 $187,000
Q2 2018

Aug 14, 2018

SELL
$7.96 - $13.23 $42,267 - $70,251
-5,310 Reduced 64.95%
2,866 $23,000
Q1 2018

May 15, 2018

BUY
$6.6 - $13.91 $17,259 - $36,374
2,615 Added 47.02%
8,176 $83,000
Q4 2017

Feb 14, 2018

BUY
$5.89 - $7.21 $25,756 - $31,529
4,373 Added 368.1%
5,561 $36,000
Q3 2017

Nov 14, 2017

BUY
$4.43 - $6.58 $5,262 - $7,817
1,188
1,188 $8,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $102M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.